Researcher developing pancreatic cancer treatment that targets newly identified protein
MSN highlights Cancer Center trainee associate member
MSN highlighted the University of Cincinnati Cancer Center’s Ahmet Kaynak's research that examined the unique tumor microenvironment of pancreatic ductal adenocarcinoma cells, identified one of the key proteins that aids tumor treatment resistance and developed a new drug targeting this protein that reduced tumor size and increased survival in animal models.
The tumor microenvironment is the ecosystem that includes the tumor and surrounding immune cells, blood vessels and other tissue. Kaynak said PDAC’s microenvironment has unique characteristics that suppress the immune system’s ability to attack the cancer cells (causing immunosuppression), hinder drug delivery, and promote resistance to chemotherapy, radiotherapy and immunotherapy.
“There is an unmet need for the development of novel treatment approaches,” said Kaynak, PhD, a trainee associate member of the Cancer Center and postdoctoral fellow in the Hematology & Oncology Division of the Department of Internal Medicine in UC’s College of Medicine. “In this project, we asked the question of what the factors are that lead to immunosuppression in the tumor microenvironment.”
Kaynak and colleagues identified that a protein called Hsp70 contributes to tumor immunosuppression.
The team then developed a drug called SapC-DOPG that specifically targets cancer cells by binding to phosphatidylserine, a lipid on the cells’ surface. This work builds upon that of Kaynak’s mentor, Xiaoyang Qi, PhD, who developed a similar drug called SapC-DOPS that is currently in Phase 2 clinical trials as a lung cancer treatment.
SapC-DOPG was designed to target Hsp70 within PDAC cells. In animal models of PDAC, the drug was well tolerated and resulted in smaller tumor size and increased survival.
“We hope to transition to clinical settings and investigate whether SapC-DOPG can be used as a therapeutic agent in pancreatic cancer patients,” Kaynak said. “The safety of the analog SapC-DOPS has been proven in clinical trials with patients. We hope our novel drug can also be safely used in patients in the future.”
Read the original UC News story.
Featured photo at top of Kaynak in the lab. Photo/provided.
Related Stories
Tips to avoid headaches this holiday season
December 15, 2025
A University of Cincinnati migraine expert offered a list of potential headache triggers around the holidays, and how you can try to avoid them, to 91.7 WVXU News. "There are a number of different factors that make this a very headache provocative time," said Vincent Martin, MD, professor of clinical medicine at the University of Cincinnati's College of Medicine and director of the Headache and Facial Pain Center at the Gardner Neuroscience Institute.
Local couple uses royalties from children's books to give gifts to kids in need
December 15, 2025
A local couple has found a unique way to give back to those in need this holiday season. Vic and Laura Troha wrote two children's books together, and this year, they are using the proceeds to buy Christmas gifts for Hamilton County foster kids. The couple are both graduates of the University of Cincinnati's College of Allied Health Sciences and met the day they graduated.
The hottest toys this holiday season
December 15, 2025
Local 12 turned to Lindner College of Business associate professor-educator of marketing Roseann Hassey to explain what’s got the trendiest items flying off the shelves.